Trevi Therapeutics, Inc. Convertible Preferred Stock, Shares Issued upon Conversion
Trevi Therapeutics, Inc. (TRVI) had Convertible Preferred Stock, Shares Issued upon Conversion of 10.38 million shares as of 2019-05-09, per its 10-K filed 2021-03-25.
Discontinued › Notes › Stockholders' Equity Note › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion · last filed 2021-03-25
- 2019-05-09: Convertible Preferred Stock, Shares Issued upon Conversion 10.38M shares.
| Period end | Convertible Preferred Stock, Shares Issued upon Conversion |
|---|---|
| 2019-05-09 | 10.38M shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |